Hepatitis C infection in patients with chronic kidney disease

International Journal of Artificial Organs

Volumn 31, Issue 1, 2008, Pages 15-33

  Mangia, A ^a   Burra, P ^b   Ciancio, A ^c   Fagiuoli, S ^d   Guido, M ^b   Picciotto, A ^e   Fabrizi, F ^f  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Chronic kidney disease; Dialysis; Hepatitis C; Renal transplantation

Indexed keywords

DISEASE CONTROL; PATIENT TREATMENT; VIRUSES;

ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; HEPATITIS C; HEPATITIS C VIRUS; INFECTED PATIENTS; RENAL TRANSPLANTATION; RENAL TRANSPLANTS; RETROSPECTIVE SURVEYS; VIRUS SPREADS;

DIALYSIS;

ALPHA INTERFERON; AMANTADINE; ANGIOTENSIN ANTAGONIST; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ERYTHROPOIETIN; INTERFERON; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RAPAMYCIN; RIBAVIRIN; RNA ANTIBODY; THYMOCYTE ANTIBODY; VIRUS RNA;

ANEMIA; AREA UNDER THE CURVE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE POLICY; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; INFECTION RISK; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; POSTOPERATIVE INFECTION; PREVALENCE; REVIEW; SCREENING TEST; STAFF TRAINING; SURVIVAL RATE; SYSTEMATIC REVIEW; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 41049091748     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100104     Document Type: Review

References (148)

1. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P, and the HCV Collaborative Group. The changing epidemiology of hepatitis C virus (HCV) infection in hemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-9.
2. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, Casalino C, Ippolito G. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-10.
3. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
4. Zampieron A, Javaseken H, Elseviers M, Lindley ME, De Vos JY, Visser R, Harrington M. European study on epidemiology and management of hepatitis C virus infection in the hemodialysis population. Part 3: prevalence and incidence. EDTNA ERCA J 2006; 32: 42-4.
5. Fabrizi F, De Vecchi A, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen assay. Aliment Pharmacol Ther 2005; 21: 861-9.
6. Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S, The Lazio Dialysis Registry. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian Region. Am J Kidney Dis 2006; 48: 629-37.
7. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
8. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-6.
9. Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation on HCV infection among dialysis patients (Survey by the Italian Branch of EDTNA/ ERCA). J Nephrol 1999; 12: 322-7.
10. Perez RM, Ferraz ML, Figueiredo MS, Contado D, Koide S, Ferreira AP, Cendoroglo Neto M, Medina Pestana JO, Silva E. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69: 489-94.
11. Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, Kakavas J, Kakapothaki V, Boletis J, Hatzakis A. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005; 45: 334-43.
12. Batty DS, Swanson SWJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-84.
13. Ghamdi SM, Al-Harbi AS. Hepatitis C virus sero-status in hemodialysis patients returning from holidays: another risk factor for HCV transmission. Saudi J Kidney Dis Transplant 2001; 12: 14-20.
14. Kashem A, Nusairat I, Mohamad M. Hepatitis C virus among HD patients in Najran: prevalence is more among multicenters visitors. Saudi J Kidney Dis Transplant 2003; 14: 206-11.
15. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004; 65: 2335-42.
16. Arenas MD, Sanchez-Paya J, Gonzalez C, Rivera F, Antolin A. Audit on the degree of application of universal precautions in a hemodialysis unit. Nephrol Dial Transplant 1999; 14: 1001-3.
17. Arenas MD, Sanchez-Paya J, Barril G, Garcia-Valdecasa J, Gorriz JL, Soriano A, Antolin A, Lacueva J, Garcia S, Sirvent A, Espinosa M, Angoso M. A multicentric survey of the practice of hand hygiene in hemodialysis units: factors affecting compliance. Nephrol Dial Transplant 2005; 20: 1164-71.
18. CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR 2001; 50 RR-5: 1-41.
19. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-5.
20. Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron 1995; 70: 301-6.
21. Saab S, Martin P, Brezina M, Gitnick G, Yee HF. Serum Alanine Aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 2001; 37: 308-15.
22. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive parients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-02.
23. Stehman-Breen C, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with HCV. Am J Kidney Dis 1998; 32: 629-34.
24. Espinosa M, Martin-Maio A, Alvarez de Lara MA, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term hemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-74.
25. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis Aliment Pharmacol Ther 2004; 20: 1271-7.
26. Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRID patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 1013-8.
27. Godkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOOPS). J Am Soc Nephrol 2003; 14: 3270-7.
28. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9.
29. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive hemodialysis patients: a population-based study. Nephrol Dial Transplant 2005; 20: 1662-9.
30. Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, Etoh Y, Shigematsu M, Kashiwagi S. Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-1600.
31. Espinosa M, Martin-Maio A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aijama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58: 143-50.
32. Gursoy M, Gur G, Arsian H, Ozdemir N, Boycioglu S. Interferon therapy in hemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-7.
33. Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M. Dialysis-membrane-dependent reduction and adsorption of circulating hepatitis C virus during hemodialysis. Nephron 2002; 91: 235-42.
34. Ishida H, Tanabe K, Tokumoto T, Shimizu T, Shimura H, Yoshioka T, Toma H. Hepatitis C virus decreases in patients with maintenance hemofiltration therapy. Int J Artif Organs 2004; 28: 316-18.
35. Angelico M, Morosetti M, Passalacqua S, Chiappini MG, Botta S, Ombres D, Splendiani G, Casciani CU. Low levels of hepatitis C virus RNA in blood of infected patients under maintenance hemodialysis with high-biocompatibility, high permeability filters. Dig Liver Dis 2000; 32: 724-8.
36. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Salvadori M, Como G, Ponticelli C, Graziani G. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis 2003; 42: 143-50.
37. Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, Ranghino A, Silini E, Soccio G, Dal Canton A. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999; 56: 2286-91.
38. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
39. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Yokado Y, Okyama A. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-6.
40. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long term impact of hepatitis C virus infection in kidney transplant recipient. Transplantation 1998; 65: 667-70.
41. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-50.
42. Pedroso S, Martins L, Fonseca I, Dias L, Henriques AC, Sarmento AM, Cabrita. A. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc 2006; 38: 1890-4.
43. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and C virus infection in the recipients on late renal allograft failure. Nephrol Dial Transplant 2004; 19 (Suppl. 3): iii72-6.
44. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Koff JM, Holtzmuller KC, Schnitzler MA. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 3166-74.
45. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with post-transplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1370-80.
46. Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4: 1876-82.
47. Pereira BJG, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, The New England Organ Bank Hepatitis C Study Group. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374-81.
48. Akalin E, Murphy B, Segal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipient. Clin Transplant 2004; 18: 384-98.
49. Kamar N. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? Transplant Proc 2006; 38: 1329-32.
50. Fabrizi F, Bromberg J, Elli A, Dixit V, Martin P. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment Pharmacol Ther 2005; 22: 657-66.
51. Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, Garcia-Retortillo M, Garcia-Valdecasas JC, Rodes J. Beneficial effects of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-92.
52. Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998; 27: 2-6.
53. Toth CM, Pascual M, Chung RT, Greme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254-8.
54. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus on renal graft and patient survival: A 9-year prospective study. Am J Kidney Dis 2004; 43: 131-9.
55. Forman JP, Tolkoff-Rubin N, Pascual M, Lin J. Hepatitis C acute humoral rejection and renal allograft: survival. J Am Soc Nephrol 2004; 15: 3249-55.
56. Gentil MA, Rocha JL, Rodriguez-Algarra G, Pereira P, Lopez R, Bernal G, Munoz J, Narajo M, Mateos J. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1994; 14: 2455-60.
57. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-61.
58. Cosio G, Sedmak DD, Henry ML, Al Haddad C, Falkenhain ME, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-9.
59. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J. De novo membranoproliferative glomerulonephritis in hepatitis C virus infected renal allograft recipients. Transplantation 1995; 59: 1676-82.
60. Morales JM, Pascual-Capdevila J, Campistol JM, Fernandez-Zatarain G, Munoz MA, Andres A, Praga M, Martinez MA, Usera G, Fuertes A, Oppenheimer F, Artal P, Darnell A, Rodicio JL. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63: 1634-9.
61. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-5.
62. Cruzado JM, Carrera M, Torras J, Grinyo JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-8.
63. Hestin D, Guillemin F, Castin N, Le Faou A, Champigneulles J, Kessler M. Pretransplant hepatitis C virus infection. A predictor of proteinuria after renal transplantation. Transplantation 1998; 65: 741-4.
64. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-9.
65. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2003; 80 (Suppl 2): S254-64.
66. Ridruejo E, Mandò OG, Davalos M, Diaz C, Viches A. Hepatocellular carcinoma development in renal allograft recipients. Transplant Proc 2005; 37: 2086-8.
67. Aroldi A, Lampertico P, Montagnino G, Lunghi G, Passerini P, Villa M, Campise M, Cesana BM, Ponticelli C. Natural history of hepatitis C virus infection in adult renal graft recipients. Transplant Proc 2005; 37: 940-1.
68. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Clesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-9.
69. Yasuda K, Okuda K, Endo N. Hypoaminotransferasemia in patients undergoing long term hemodialysis clinical and biochemical appraisal. Gastroenterology 1995; 109: 1295-9.
70. Guh J, Lai Y, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 99: 1969-74.
71. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998; 80: 428-33.
72. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Soriano S, Alijama P. High ALT levels predict viremia in anti-HCV positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000; 54: 151-6.
73. Schneeberger PM, Keur I, Van der Kliet W, Van Hoek K, Boswijk H, van Loon AM, Van Dijk WC, et al. Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36: 1711-5.
74. Sterling R, Sanyal A, Luketic V, Stravitz R, King A, Post A, Mills A, Contos M, Shiffman M. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting liver transplantation. Am J Gastroenterol 1999; 94: 3576-81.
75. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Kinetics of hepatitis C virus load during hemodialysis: novel prospectives. J Nephrol 2003; 18: 467-75.
76. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G. Histopatological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 1479-83.
77. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37.
78. Mouquet C, Mathurin P, Sylla C, Benalia H, Opolon P, Coriat P, Bitker MO. Hepatic cirrhosis and kidney transplantation outcome. Transplant Proc 1997; 29: 2406.
79. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, Bedossa P, Brechot C. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35: 107-12.
80. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
81. Manns MP, McHutchison ML, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
82. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J. Peginterferon alpfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
83. Rao KV, Anderson RW, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94: 241-50.
84. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalbas B, Imbertbismuth F, Lebray P, Pol S. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005; 80: 1550-5.
85. Hestin D. Hepatitis C after renal transplantation: histopathological correlations. Nephrol Dial Transplant 1996; 11 (Suppl 4): S52-3.
86. Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C positive patients and renal transplant recipient. Am J Gastroenterol 1999; 94: 159-63.
87. Pol S, Debure A, Degott C, Carnot F, Legendre C, Brechot C, Kreis H. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 25: 1450-3.
88. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52; 843-61.
89. Giordano HM, Alex FV, Escanhoela CA, Nishimura NF, Santos RL, Quadros KL, Mazzali M, Alves-Filo G, Soares EC. Chronic liver disease in kidney recipient in hepatitis C virus infection. Clin Transplant 2003; 17: 195-9.
90. Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, Lunghi G, Tarantino A, Cesana BM, Messa P, Ponticelli C. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-36.
91. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Pèron JM, Vinel JP, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.
92. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Brechot C, Pol S. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-33.
93. Perez RM, Ferreira AS, Medina-Pestana JO, Cendoroglo-Neto M, Lanzoni VP, Silva EB, Ferraz MLG. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006; 40: 444-8.
94. Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, Cillo U, Naccarato R, Rugge M. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700.
95. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004; 24: 69-77.
96. Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyakee S, Sakai T, Akiba T, Marumo F. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 51-6.
97. Rostaing L, Chatelut E, Payen JL, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
98. Russo MW, Goldsweig C, Iacobson M, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5.
99. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81.
100. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Chaumet P, Chevret V. The tolerance and efficacy of interferon-a in hemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.
101. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brèchot C. Efficacy and tolerance of a2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8.
102. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, Pestana JO, Lanzoni VP, Silva E, Ferraz ML. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26: 305-10.
103. Yildirim B, Durak H, Ozaras R, Canbakan B, Ozkan P, Ozbay G, Senturk H. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment. Scand J Gastroenterol 2006; 41: 1235-41.
104. Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transplant 2006; 17: 338-43.
105. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Consensus interferon study group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787-93.
106. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19: 17-24.
107. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001; 8: 287-92.
108. Mousa DH, Abdalla AH, Al-Shoail A, Al-Sulaiman H, Al-Hawas FA, Al-Khader A. Alpha interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4.
109. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. Safety of interferon and ribavirin therapy in hemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-5.
110. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-9.
111. Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, Carretero D, Alvarez-Lara MA, Carnicer F, Martin-Malo A, Aljama P. Anemia associated with pegylated interferon alpha-2a and alpha-2b therapy in hemodialysis patients. Clin Nephrol 2007; 67: 366-73.
112. Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40KDA) interferon alfa-2a (Pegasys™) is unaffected by renal impairment. Hepatology 2000; 32: 842 A.
113. Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, Carreno V. Pegylated interferon-alpha2a kinetics during experimental hemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 2004; 20: 37-44.
114. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-43.
115. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantacerken B, Buyukbese MA, Isik IO. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-80.
116. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C. Pegylated interferon alpha 2a treatment for chronic hepatitis C in patients on chronic hemodialysis. World J Gastroenterol 2006; 14: 4191-4.
117. Annicchiarico BE, Siciliano M. Pegylated interferon alpha 2b monotherapy for HD patients with chronic HCV. Aliment Pharmacol Ther 2004; 20: 123-7.
118. Teta D, Landtwing Luscher B, Gonvers J, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in hemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3.
119. Covic A, Maftei ID, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006; 19: 794-801.
120. Casanovas-Taltavull T, Baliellas C, Llobet M, Cruzado JM, Castellote J, Casanova A, Niubo J, Valls C, Serrano T. Preliminary results of treatment with pegylated interferon alpha2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007; 39: 2125-7.
121. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in hemodialysis patients. J Viral Hepat 2006; 13: 316-21.
122. Rendina M, Castellaneta NM, Castellaneta A, Losito A, Schena A, Stallone G, Schena FP, Francavilla AV. The treatment of chronic hepatitis C with peginterferon alpha2a (40 kDA) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 764-8.
123. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-31.
124. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD. Ultralow-close alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894-905.
125. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Ho Y, Leung LK, Chan TM. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha 2b and ribavirin. J Hepatol 2003; 39: 875-8.
126. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-22.
127. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S. Histopathological efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-57.
128. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110-14.
129. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-8.
130. Bunnapradist S, Fabrizi F, Vierling J, Martin P, Moudgil A, Kamil E, Jordan S. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 2002; 25: 1189-93.
131. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-60.
132. Criteri generali per la valutazione della idoneità del donatore. CNT, 1 March 2005. Available at web site: www.cnt.org
133. Dalladetsima I, Psichogiou M, Sypsa V, Psimenou E, Kostakis A, Hatzakis A, Boletis JN. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow up study. Am J Kidney Dis 2006; 47: 309-16.
134. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors: a safe strategy? Int J Artif Organs 2003; 5: 617-28.
135. Morales JM, Campistol M, Castellano G, Andres A, Colina F, Fuertes A, Ercilla G, Bruguera M, Andreu J, Carretero P. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47: 236-40.
136. Ali MK, Light JA, Barryte DY, Sasaki TM, Currier CB, Grandas O, Fowlkes D. Donor hepatitis virus status does not adversely affect short-term outcomes in HCV positive recipients in renal transplantation. Transplantation 1998; 66: 1694-7.
137. Mandal AK, Kraus ES, Samaniego M, Rai R, Humphreys SL, Ratner LE, Maley WR, Burdick JF. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000; 14: 391-6.
138. Woodside KJ, Ishihara K, Theisen JE, Early MG, Covert LG, Hunter GC, Gugliuzza KK, Daller JA. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-year outcome. Clin Transplant 2003; 17: 433-7.
139. Veroux P, Veroux M, Sparacino V, Giuffrida G, Puliatti C, Macarone M, Fiammingo P, Cappello D, Gagliano M, Spataro M, Di Mare M, Cannizzaro MA, Severino V. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006; 38: 996-8.
140. Meier-Kriesche HU, Schold JD, Gaston RS, Waldstrom J, Kaplan B. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant 2005; 5: 1725-30.
141. Abbott KC, Bucci YR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Cruess DF, Peters TG. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-18.
142. Protocollo CNT per l'utilizzo di donatori HCV+ in riceventi trapianto di rene HCV+. CNT, 1 August 2003. Available at web site: www.cnt.org
143. Morales JM, Campistol JM, Andres A, Dominguez-Gil B, Esforzado N, Oppenheimer F, Rodicio JL. Use of kidney from anti-HCV positive donors. Transplant Proc 2001; 33: 1776-7.
144. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewskii RR, Mushahwar IK, Desai SM, Miller RH, Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-40.
145. Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642-7.
146. Schussler T, Staffeld-Loit C, Eason J, Nair S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am J Transplant 2004; 4: 1375-8.
147. Natov SN, Lau JY, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, Pereira BJG. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998; 31: 920-7.
148. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-7.